ArticleOncology letters2026
Meta-analysis of efficacy comparisons between standard- and low-dose Bacillus Calmette-Guerin vaccines in managing non-muscular invasive bladder cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravesical Bacillus Calmette-Guerin (BCG) is the first-line therapy for non-muscle-invasive bladder cancer (NMIBC), yet its clinical use is limited by high adverse event rates and a global supply shortage. A comparison was conducted to explore the effectiveness of low- vs. standard-dose BCG vaccines in patients diagnosed with NMIBC). The search queries utilized for China National Knowledge Infrastructure and Wanfang databases included the key words 'dose', 'BCG vaccine' and 'bladder cancer/bladder tumour'. Embase, PubMed and Web of Science databases were searched using the key words 'dose', 'Bacillus Calmette-Guerin vaccine' and 'urinary bladder neoplasm' to identify randomized controlled trials published up to December 2024. The relevant data were collected from the included study articles and a meta-analysis was conducted utilizing the Review Manager 5.4 software to evaluate the therapeutic effects of low- and standard-dose BCG vaccines. In total, 13 studies were included in the present meta-analysis after literature search, selection process and quality assessment. The present meta-analysis findings suggested that the recurrence rate in patients receiving low-dose therapy was notably higher compared with that in patients receiving standard-dose therapy [odds ratio (OR)=1.38; 95% CI, 1.10-1.73; P=0.006]. However, the incidence of adverse events was lower compared with that in the standard-dose treatment group (OR=0.39; 95% CI, 0.29-0.52; P<0.00001) and no marked differences in tumour progression, tumour-specific or overall mortalities were detected between the two groups (all P>0.05). The funnel plot revealed no notable publication bias. In conclusion, the present meta-analysis confirmed the effectiveness of low-dose BCG treatment for patients with NMIBC and highlighted its potentially notable advantage in managing adverse events in patients with NMIBC in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.